Clinical use of High-Dose Neuroleptics

1994 ◽  
Vol 164 (1) ◽  
pp. 94-96 ◽  
Author(s):  
Steven R. Hirsch ◽  
Thomas R. E. Barnes
Keyword(s):  
British National Formulary ◽  
High Dose ◽  
Clinical Use ◽  
National Formulary ◽  
Public Concern ◽  
Neuroleptic Treatment ◽  
Clinical Issues ◽  
Small Minority ◽  
Dose Treatment ◽  
High Dose Treatment

There has been increasing public concern about the risks of high-dose antipsychotic (neuroleptic) treatment, arising in part from an, as yet unproven, association between high-dose treatment and death in a small minority of patients. The clinical issues related to the use of neuroleptics in doses exceeding the maximum recommended in theBritish National Formulary(BNF) were discussed at the Psychopharmacology Subcommittee. When, if ever, should the recommended doses be exceeded?

P162 clinical pharmacokinetics of etoposide during high-dose treatment in relation to toxicity

1994 ◽  
Vol 2 (1-2) ◽  
pp. 159
Author(s):  
S. Stremetzne ◽  
U. Jaehde ◽  
J. Beyer ◽  
J. Steuer ◽  
W. Siegert ◽  
...  
Keyword(s):  
High Dose ◽  
Clinical Pharmacokinetics ◽  
Dose Treatment ◽  
High Dose Treatment

Safety and Efficacy of Combined High-Dose Treatment with Calcipotriol Ointment and Solution in Patients with Psoriasis

Dermatology ◽  
2002 ◽  
Vol 204 (3) ◽  
pp. 214-221 ◽  
Author(s):  
P.C.M. van de Kerkhof ◽  
C. Green ◽  
K.J. Hamberg ◽  
P.E. Hutchinson ◽  
J.K. Jensen ◽  
...  
Keyword(s):  
High Dose ◽  
Safety And Efficacy ◽  
Dose Treatment ◽  
High Dose Treatment

Phase I study evaluating high-dose treatment with ADXS11-001, a Listeria monocytogenes-listeriolysin O (Lm-LLO) immunotherapy, in women with cervical cancer.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e14580-e14580 ◽  
Author(s):  
Sharad A. Ghamande ◽  
Daniel Platt ◽  
Donna Wheatley ◽  
Bunja Jane Rungruang ◽  
John Edward Janik ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Listeria Monocytogenes ◽  
Phase I ◽  
Phase I Study ◽  
High Dose ◽  
Listeriolysin O ◽  
Dose Treatment ◽  
High Dose Treatment

EFFECT OF REPETITIVE HIGH-DOSE TREATMENT WITH SOLUBLE COMPLEMENT RECEPTOR TYPE 1 AND COBRA VENOM FACTOR ON DISCORDANT XENOGRAFT SURVIVAL1,2

1996 ◽  
Vol 62 (3) ◽  
pp. 336-342 ◽  
Author(s):  
Daniel Candinas ◽  
Beth-Ann Lesnikoski ◽  
Simon C. Robson ◽  
Tsukasa Miyatake ◽  
Susanne M. Scesney ◽  
...  
Keyword(s):  
Receptor Type ◽  
Cobra Venom ◽  
High Dose ◽  
Complement Receptor ◽  
Cobra Venom Factor ◽  
Dose Treatment ◽  
Complement Receptor Type ◽  
High Dose Treatment ◽  
Complement Receptor Type 1

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.

1994 ◽  
Vol 12 (10) ◽  
pp. 2022-2034 ◽  
Author(s):  
D C Ihde ◽  
J L Mulshine ◽  
B S Kramer ◽  
S M Steinberg ◽  
R I Linnoila ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Standard Dose ◽  
Small Cell ◽  
High Dose ◽  
Small Cell Lung ◽  
Dose Treatment ◽  
High Dose Treatment ◽  
Extensive Stage ◽  
To Receive ◽  
Higher Doses

PURPOSE We performed a prospective randomized clinical trial to determine whether higher doses of etoposide and cisplatin (EP) yield more complete responses or longer survival in small-cell lung cancer (SCLC) patients. PATIENTS AND METHODS Ninety patients with previously untreated extensive-stage SCLC fulfilled criteria for randomization to standard-dose versus high-dose EP. Another 25 patients at risk of excessive toxicity from high-dose treatment were given standard-dose therapy. During cycles 1 and 2 of EP, patients on standard-dose treatment received intravenous etoposide 80 mg/m2 on days 1 to 3 and cisplatin 80 mg/m2 on day 1 every 3 weeks; high-dose treatment consisted of etoposide 80 mg/m2 on days 1 to 5 and cisplatin 27 mg/m2 on days 1 to 5 every 3 weeks. All patients received standard-dose EP in cycles 3 and 4. In cycles 5 through 8, completely responding patients continued standard-dose EP; all other patients received either cyclophosphamide, doxorubicin, and vincristine, or (if possible) a combination drug program based on in vitro drug sensitivity testing of tumor-cell lines established from individual patients. RESULTS Despite 68% higher doses and a 46% higher dose-rate intensity actually given to patients randomized to receive high-dose relative to those randomized to receive standard-dose EP, complete response rates (23% v 22%; P = .99) and median survival durations (10.7 and 11.4 months, respectively; P = .68) were virtually identical. Complete responses occurred in 4% of patients and the median survival duration was 5.8 months in nonrandomized patients. Leukopenia (P < .0001), thrombocytopenia (P < .0001), febrile neutropenia (P = .01), and weight loss (P = .02) were significantly more common in patients randomized to receive high-dose compared with standard-dose EP. CONCLUSION No therapeutic benefits resulted from increasing planned doses by 67% for the first two cycles of EP in patients with extensive-stage SCLC. Higher doses were associated with substantially worse toxicities.

Sign in / Sign up

Export Citation Format

Share Document